














The Effect of Gefapixant, a P2X3 antagonist, on 




Alyn H. Morice, Michael M. Kitt, Anthony P. Ford, Andrew M. Tershakovec, Wen-Chi Wu, Kayleigh 




Please cite this article as: Morice AH, Kitt MM, Ford AP, et al. The Effect of Gefapixant, a 
P2X3 antagonist, on Cough Reflex Sensitivity: A randomised placebo-controlled study. Eur 







This manuscript has recently been accepted for publication in the European Respiratory Journal. It is 
published here in its accepted form prior to copyediting and typesetting by our production team. After 
these production processes are complete and the authors have approved the resulting proofs, the article 




Copyright ©ERS 2019 
 
The Effect of Gefapixant, a P2X3 antagonist, on Cough Reflex Sensitivity: A randomized placebo-
controlled study 
Alyn H Morice1; Michael M Kitt2; Anthony P Ford2; Andrew M Tershakovec2; Wen-Chi Wu2; Kayleigh 
Brindle1; Rachel Thompson1; Susannah Thackray-Nocera1; Caroline Wright1  
1Hull York Medical School, Cottingham, UK; 2 Merck & Co., Inc., Kenilworth, NJ USA 
 
Corresponding Author: 
Prof. Alyn H Morice, MD FRCP FBPhS 
Respiratory Medicine  
Hull York Medical School, University of Hull, Castle Hill Hospital 
Castle Road  
Cottingham, East Yorkshire, HU16 5JQ, UK.  
e-mail: a.h.morice@hull.ac.uk. 
 




Gefapixant reduces coughing in patients and blocks ATP and distilled-water-induced cough, but not 
cough evoked by citric acid or capsaicin, thus suggesting a unique a TRPV4/ATP pathway may 
underlie cough hypersensitivity seen in chronic refractory cough.  
 
Abstract 
Introduction: We evaluated the effect of gefapixant on cough reflex sensitivity to evoked tussive 
challenge. 
Methods: In this Phase 2, double-blind, 2-period study, chronic cough subjects (CC) and healthy 
volunteers (HV) were randomized to single-dose gefapixant 100 mg or placebo in crossover fashion. 
Sequential inhalational challenges with ATP, citric acid, capsaicin, and distilled water were 
performed 1, 3 and 5 hours after dosing.  Mean concentrations evoking ≥2 (C2) and ≥5 (C5) 
coughs post dose vs. baseline were co-primary endpoints. Objective cough frequency (coughs/hr) 
over 24 hours, and Cough Severity Visual Analogue Scale (VAS) were assessed in CC.  Adverse events 
(AE) were monitored. 
Results: 24 CC and 12 HV were randomized (mean age 61 and 38 years, respectively).  Cough 
challenge threshold increased for ATP by 4.7-fold (C2, p=<0.001) and 3.7-fold (C5, p=0.007) for 
gefapixant vs placebo in CC; in HV, C2 and C5 increased 2.4-fold (C2, p=0.113; C5, p=0.003).  Distilled 
water C2 and C5 were increased significantly (p<0.001), by a factor of 1.4 and 1.3, respectively, in CC.  
Gefapixant had no effect on capsaicin or citric acid challenge.  Median cough frequency was reduced 
by 42% and least-squares (LS) mean Cough Severity VAS was 18.0 mm lower for gefapixant vs. 
placebo in CC subjects. Dysgeusia was the most frequent AE (75% HV and 67% CC).  
Conclusions: ATP-evoked cough was significantly inhibited by gefapixant 100 mg demonstrating 
peripheral target engagement.  Cough count and severity were reduced in CC. Distilled water may 
also evoke cough through a purinergic pathway.  




Chronic cough (CC; i.e., cough lasting ≥8 weeks) has been reported in up to 10% of the general 
population [1, 2]. Patients often experience physical, social, and psychological effects from 
paroxysms of coughing that may be as frequent as hundreds or even thousands of times each day 
persisting for months or years [3-8].  
CC patients may have underlying disorders including asthma, pulmonary fibrosis, lung 
cancer, chronic obstructive pulmonary disease (COPD), rhinitis, gastroesophageal reflux or 
oesophageal dysmotility or they may have unexplained chronic cough (UCC) where no associated 
condition can be identified. In refractory chronic cough (RCC) patients, conventional treatment of 
underlying disorders are frustratingly inadequate in ameliorating bouts of coughing.  Many patients 
also exhibit a hypersensitivity to external stimuli such as a change in temperature, strong smells, and 
aromatics which are mysterious to both the patient and their doctor [9]. Cough hypersensitivity 
syndrome (CHS) is an overarching diagnosis for patients with exquisite sensitivity to otherwise 
innocuous stimuli [10]. 
Cough challenge with inhaled tussive agents has been used to assess cough reflex response 
for several decades [11]. The most common challenge agents include citric acid, capsaicin, and fog 
(i.e., distilled water), which stimulate cough through various peripheral nerve receptors in the 
airways [12]. Adenosine triphosphate (ATP) has also been shown to induce cough in conditions such 
as asthma and COPD [13-15].  More recently, ATP challenge has been characterized in normal and 
chronic cough patients, and although patients do exhibit a heightened cough reflex, the difference in 
sensitivity is surprisingly small. [16]. Thus, the role of ATP in cough reflex sensitivity remains to be 
fully elucidated.  
P2X3 receptors are ligand-gated ion channels that respond to ATP. Medications targeting 
these receptors may treat patients through normalization of afferent sensitivity, specifically 
afferents that innervate the upper and lower airways[17]. Gefapixant is a P2X3 receptor antagonist 
 
that has demonstrated efficacy in the treatment of RCC [18]. To further elucidate the role of 
purinergic mechanisms in the cough reflex, we conducted a study of gefapixant on cough reflex 
sensitivity to four inhaled challenge agents; ATP, distilled water, capsaicin, and citric acid, in both 
healthy volunteers (HV) and CC subjects. Our hypothesis was at that gefapixant would differentially 
affect cough reflex sensitivity dependent on the modality of challenge agent used. 
 
Methods 
This double-blind, randomized, 2-period, crossover study (Protocol 014; Clinical Trials Registry 
NCT02476890) in HV and CC subjects was conducted at a single site (Hull York Medical School, 
Cottingham, UK) in accordance with principles of Good Clinical Practice and was approved by the 
Yorkshire and Humber, Sheffield Research Ethics Committee (Jarrow, UK). Subjects provided 
informed consent prior to being enrolled in the study. 
Subjects 
Enrolled HV and CC subjects were between 18 and 80 years of age, inclusive, and were non-smokers 
for at least 5 years. Healthy subjects had a forced expiratory volume in 1 second (FEV1) ≥80% at 
Screening. CC subjects had refractory cough for ≥ 1 year (cough unresponsive to ≥ 8 weeks of 
treatment for underlying conditions including reflux disease, asthma, or rhinitis) and demonstrated 
significant cough symptoms by a score > 20/70 on the Hull Airway Reflux Questionnaire (HARQ). 
Additional exclusion criteria are provided in the Supplementary Appendix. 
 
Study Design 
After screening, there was a baseline visit before each of two, 1-day treatment periods that were 
separated by a minimum 48-hour washout period. Treatment consisted of gefapixant 100 mg (2 
 
gefapixant 50-mg tablets) and placebo (2 matching placebo tablets). Treatments were administered 
in a double-blind fashion where subjects and study personnel were blinded to treatment codes. 
Subjects were assigned to one of two treatment sequences based on a computer-generated 
randomization schedule using a permuted block algorithm to allocate subjects’ numbers. 
Stratification was used (HV vs. CC subjects). An equal number of subjects were randomly assigned to 
each sequence. 
At Baseline and during each Treatment Period, cough reflex sensitivity was measured by 
determining C2 (lowest concentration of inhaled solution required to evoke ≥2 coughs) and C5 
(lowest concentration of inhaled solution required to evoke ≥5 coughs) for four separate cough 
challenges (ATP, capsaicin, citric acid, and distilled water).  The cough challenges were performed in 
the morning of each Baseline visit, and 1, 3, and 5 hours after dosing during the Treatment Periods. 
Objective cough monitoring (from the end of the cough reflex sensitivity challenge to the following 
day (up to 24 hours) was performed at Baseline and during each of the two Treatment Periods in 
subjects with chronic cough. Subjects returned two weeks after their last treatment visit for a 
Follow-Up Visit. 
The challenge agents were prepared by dilution of stock solutions with saline. The following 
pre-defined concentration ranges were used for each challenge agent:  ATP (0.1 mM, 0.3 mM, 1 mM, 
3 mM, 10 mM, 30 mM, 100 mM, 300 mM); Capsaicin (0.3 μM, 1 μM, 3 μM, 10 μM, 30 μM, 100 μM, 
300 μM, 1000 μM); Citric Acid (1 mM, 3 mM, 10 mM, 30 mM, 100 mM, 300 mM, 1M, 3M); Distilled 
Water: 20%, 40%, 60%, 80%, of 100% of distilled water in 0.9% saline). Capsaicin and citric acid were 
obtained from the NHS manufacturing pharmacy, Stockport, UK. ATP was obtained from Sigma 




Primary and Secondary Endpoints 
The concentration of the challenge agents inducing ≥2 (C2) and ≥5 coughs (C5) were assessed at 1, 
3, and 5 hours after exposure; for distilled water, the number of coughs generated during 1 minute 
of exposure was recorded. The co-primary endpoints were C2 and C5 for each challenge averaged 
across the 3 time points.   
Secondary efficacy endpoints included cough severity visual analogue scale (VAS), urge-to-
cough VAS, cough frequency, and total HARQ score in CC subjects. CC subjects completed the two 
VAS (100-mm scale) at Screening and one hour after the final cough challenge during the Treatment 
Periods; cough severity was scored from “No Cough‟ to “Worst Cough‟ urge to cough was scored 
from “No urge-to-cough‟ to “Worst urge-to-cough‟ during the previous 1 hour.  
To measure cough frequency, an ambulatory recording device was utilized [19]. Change 
from Baseline in objective cough frequency and urge-to-cough was measured during Treatment 
Periods 1 and 2 (up to 24 hours for each measure). Recordings were started at the end of cough 
challenge protocol and continued until the following day.  Each clock hour was compared across the 
three days of recording.  A minimum of 5 hours synchronous and contiguous recording was required 
before data was considered eligible for analysis. 
The HARQ (completed at Screening and 1-hour post dose during the Treatment Periods) 
comprises 14 items, each with a score ranging from ‘0’ (no problem) to ‘5’ (severe/frequent 
problem) [20]. The total HARQ score is the sum of these 14 item scores with a maximum total score 
of 70. 
Safety Evaluation 
Safety was assessed through monitoring of adverse events (AE)/serious AEs, physical examinations, 
vital signs, 12-lead ECGs, and clinical laboratory tests (hematology, chemistry, and urinalysis).  
 
Statistical Methods 
For each challenge, CC subjects and HV were analyzed separately. C2 and C5 analyses were also 
performed separately.  
Log transformation was used for the co-primary endpoints. A log C2 and C5 was generally 
regarded as normally distributed within a population, so the treatment comparisons were 
performed using a mixed effect repeated measures (MMRM) model that included fixed effects for 
period, treatment group, and all interaction terms of treatment, time point, period, and the baseline 
value (in log scale) as a covariate. The MMRM model used all available data at 1, 3, and 5 hours post 
dose. An unstructured covariance matrix was applied for the MMRM.  
For cough reflex sensitivity testing, if a subject did not achieve C2 or C5 at the maximum 
concentration of the challenge agent 1.5 times that concentration was imputed.  
Secondary endpoints for subjects with chronic cough were analyzed using a MMRM model 
that included fixed effects for period, treatment group, and the interaction term of treatment and 
period, and the period-specific baseline value as a covariate. 
Results 
Subjects 
Twenty-four CC subjects and 12 HV were randomized; all subjects completed the study and were 
included the primary efficacy population (Full analysis set [FAS]) and the safety population. Baseline 
characteristics were comparable between treatment sequences although mean age of HV was 
younger (38 years) compared with mean age for CC subjects (63 years) and more women than men 





Gefapixant was associated with an increase in the concentration of ATP and distilled water required 
to induce C2 and C5 for both healthy and chronic cough subjects, versus placebo. 
The ATP cough challenges in CC subjects showed a 4.7-fold (p=0.0006) concentration 
increase to induce C2 and a 3.7-fold (p=0.0067) increase for C5 with gefapixant versus placebo. In 
HV, a 2.4-fold (p=0.0029) increase was seen at C5 (Table 2; Figure 2) and whilst the change at C2 was 
of similar degree, it did not achieve statistical significance (Figure 3).  Distilled Water C2 and C5 
increased (p<0.05), but only by a factor of 1.4 to 1.3 in CC subjects and 1.5 (p<0.05) to 1.3 in HV.  
Capsaicin and citric acid concentrations did not increase with gefapixant for C2 and C5 in either HV 
or CC subjects (Table 2). 
Secondary endpoints  
Cough Severity VAS 
A greater reduction in change from baseline in cough severity VAS was observed with gefapixant 
versus placebo (p=0.004, Table 3).  
Urge-to-Cough Visual Analogue Scale 
A greater reduction in change from baseline in urge-to-cough VAS was observed with gefapixant 
versus placebo (p =0.002, Table 3). 
Hull Airway Reflux Questionnaire (HARQ) 
A significant reduction from baseline in HARQ total score was observed with gefapixant treatment 
although a reduction with placebo treatment was also observed and the difference for gefapixant 
versus placebo did not achieve significance (Table 3). 
  
 
Cough Frequency  
A greater reduction from baseline in cough frequency was observed with gefapixant treatment 
versus placebo (p=0.008, Table 3). 
 
Safety 
There was an increased incidence of AEs with gefapixant versus placebo in both HV and CC subjects 
(Table 4). No subject had a serious AE or an AE leading to discontinuation from the study. The most 
common AEs were related to taste (i.e., ageusia or dysgeusia). (Table 4) 
 
Discussion 
This trial demonstrated that a significant increase in ATP and distilled water concentrations were 
required to elicit two or five coughs after dosing with gefapixant 100 mg. In contrast, no effect was 
observed on capsaicin or citric acid challenge. Responses for all challenges in HV mimicked responses 
of CC, but to a lesser degree. Additionally, gefapixant 100 mg improved cough severity and 
frequency among chronic cough subjects. 
The primary function of the cough reflex is to prevent or minimize aspiration.  Those with 
conditions where cough reflex sensitivity is diminished (e.g., stroke, Parkinsonism, or dementia), 
frequently succumb to such events [21, 22].  It is unsurprising then that a series of nociceptors 
located in upper airways, attached to vagal afferents, have evolved to defend the airway against 
such insults.  The investigation of cough reflex sensitivity by inhalational tussive challenge has been 
used for over 60 years as a tool to study the physiology and clinical pharmacology of this vital 
protective reflex.  Citric acid was the first agent to be used and, although its precise mechanism of 
action  is still unclear, it is a challenge that is related to the buffered pH of the solution used [23].  
Capsaicin acts through a specific nociceptor, TRPV1, which is also acid sensitive, but has different 
 
characteristics of adaptation[24] and evoked cough can be blocked by specific TRPV1 antagonists 
[25].  Distilled water again has different attributes with very rapid adaption and marked 
tachyphylaxis. It is thought to trigger cough via osmoreceptors. Finally, the most recently described 
tussive challenge, ATP, produces a concentration-dependent increase in coughing with a slightly 
greater response seen in those with chronic cough [16]. This latter phenomenon of increased 
sensitivity to challenge agents is seen with all modalities of cough challenge, but the effect size is 
small implying that increased peripheral nociceptor sensitivity may not be a fundamental 
mechanism in the profound hypersensitivity seen in CHS [26]. 
These challenge agents are thought to act in the immediate vicinity of the airway epithelium. 
Buffering will rapidly occur with the small droplets of distilled water fog and citric acid. ATP is rapidly 
metabolized to AMP and adenosine. Capsaicin is highly lipid soluble and avidly taken up into cell 
membranes. The more central pathways of the vagal afferents through the nodose and jugular 
ganglia to the solitary nucleus are extremely complex, varied, and exhibit marked plasticity and 
redundancy in disease [27]. In this environment, the interpretation of cough challenge studies must 
be undertaken with care. 
Our finding that gefapixant led to increases in concentrations needed to induce multiple 
coughs upon ATP exposure is consistent with peripheral target engagement of the ATP-activated 
P2X3 receptors in the pathophysiology of chronic cough[28].  It suggests that release of ATP by 
airway cells may directly stimulate afferent nerves causing coughing. However, the rapid metabolism 
of ATP would imply continuous release of ATP to stimulate P2X3, a receptor with a purportedly rapid 
desensitization [29]; an observation that is compatible with the brief coughing bouts seen following 
ATP inhalation.  A notable other finding in our study was the significant, although smaller, effect of 
gefapixant with distilled water challenge.  In a recent paper, Bonvini and colleagues [30] describe a 
mechanism whereby hypo-osmolarity could lead to ATP release.  TRPV4 is a nociceptor widely 
located in the airways and is known to be activated by hypo-osmotic stimuli [31].  They show 
 
activation of TRPV4 causes a release of ATP via pannexin channels and subsequent ATP activation of 
the neuron can be blocked by a P2X3 antagonist.  Administration of a TRPV4 agonist produced 
prolonged firing of both guinea pig and human Aδ vagus nerve fibers. There was no effect of the 
antagonist on citric acid or capsaicin-sensitive C fibers. As in the current study, there was also no 
effect of P2X3 antagonism on the cough sensitivity of guinea pigs to capsaicin challenge.  
This suggests that there are at least two distinct pathways engendering the cough reflex. 
One, the TRPV4/ATP pathway responsible for cough hypersensitivity, and a second, by direct 
stimulation of nociceptors.  Inhibition of TRPV1 and TRPA1 by specific antagonists has no effect in 
chronic cough [25, 32] whereas, as we show here, even after a single dose of gefapixant, inhibition 
of ATP receptors produces a significant improvement. We believe that this is the first demonstration 
in man of two separate sensory pathways evoking cough with TRPV4/ATP as the most likely 
candidate mechanism underlying cough hypersensitivity. However chronic cough is most likely a 
heterogeneous phenomenon, triggered by a variety of peripheral mechanisms, thus explaining the 
significant subgroup of non-responders to gefapixant seen in phase two studies. Presumably cough 
in these patients is mediated via other, non-P2X2/3-related mechanisms.  
 
Gefapixant has been evaluated in patients with RCC at doses ranging from 7.5 mg to 600 mg 
twice daily (bid) [18, 33-35].  A proof-of-concept study demonstrated efficacy at the high dose of 600 
mg bid[18] and subsequent dose-ranging studies demonstrated efficacy in doses from 15 mg to 50 
mg bid with no apparent efficacy advantage with doses above 50 mg bid[33-35]. In this study, a 
single dose of gefapixant 100 mg demonstrated significant reduction in objective cough frequency 
and positive improvements in patient-reported outcomes on cough severity, urge to cough, and 
improved quality of life in chronic cough subjects. These effects after a single 100-mg dose are 
notable as patient-reported outcomes are often delayed in onset when compared with objective 
 
scores in studies of chronic cough; these findings confirm the very rapid onset of action seen with a 
P2X3 receptor antagonist. 
Results observed with ATP and, to a lesser extent, distilled water, demonstrate their possible 
utility for assessing agents that target purinergic receptors such as P2X3, although their use as a 
diagnostic tool for CHS appears to be limited. A previous study showed that although CC subjects 
had significantly more coughing at lower concentrations of ATP, they did not appear to have an 
intrinsically heightened sensitivity to ATP [16]. Perhaps this indicates that although ATP may 
constitute the final common mediator for cough hypersensitivity, it may not be the excitatory cause 
of neural sensitization. Our putative surrogate for TRPV4 activation, distilled water, had an even 
lesser response to P2X3 antagonism and has a greater degree of adaption than ATP. Both agents 
were administered direct to the airways and it may be speculated that the seat of pathological 
hypersensitivity may be located more centrally. 
Gefapixant was associated with taste disturbance AEs at the dose of 100 mg in this study. 
Although gefapixant has generally not been associated with serious AEs, taste disturbances are the 
most commonly-reported AEs[18, 33]. Previous pre-clinical research has identified P2X receptors, 
particularly P2X2/3 receptors, as playing an important role in the transmission of taste signals [36, 
37]. Studies of purinergic P2X2/3 double-genetic knockout mice have demonstrated a loss of taste-
evoked activity [38]. Previous studies with gefapixant suggest a mechanistic role in taste disturbance 
from P2X3 antagonism based on dose-related taste disturbance [33-35]. Effects on cough reduction 
were observed in lower doses where taste disturbances were more limited or minimal; Phase 3 
studies are ongoing and will provide further evidence of whether positive improvements in the 
treatment of RCC can be achieved with acceptable safety and tolerability [33-35].  
There are several important limitations to this study. Taste disturbance may well have 
influenced the results by unblinding participants. A single dose may not represent effects which 
occur with chronic therapy. A further important limitation for this study was its small sample size, 
 
which limited our ability to assess an impact from the testing order of tussive agents. However, for 
individual subjects, the order remained the same for each study day and randomisation was carried 
out between patients in a block design to minimise the risk of any order effect, which, would be 
balanced by the crossover nature of the study. Previous studies have demonstrated significant cross 
tachyphylaxis between challenges and a tendency for reduced response on repeated challenge. This 
latter phenomenon may account for the upward drift of the cough challenges with time seen in 
Figure 3. However, a post-hoc analysis of the effect of challenge order in this study has found no 
evidence of carryover between different challenges [39]. 
In summary, we demonstrated that purine ATP-evoked cough was inhibited by gefapixant 
100 mg in both HV and CC subjects, although results were more limited in HV. To a smaller, but 
statistically significant degree, coughs were also reduced following the distilled water challenge. An 
effect of gefapixant on capsaicin- or citric acid-evoked cough for either HV or CC subjects was not 
observed. Knowledge of the mechanism of drug action is required to understand the relevance of 
challenge agents in an antitussive drug-discovery model.  In this experimental design we have been 
able to differentiate at least two separate pathways for evoked cough challenge in man with the 
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Figure 1: Disposition of Subjects. Tussive challenges were administered at 1, 3, and 5 hours post 
dose. All randomized subjects were included in the Full Analysis Set for efficacy analyses as well as 
the Safety Set for evaluation of safety. All randomized subjects completed the study.  
Figure 2: C2 and C5 for ATP and Distilled Water Cough Challenges - Mixed Model Repeated 
Measures Analysis based on natural log-transformed data - FAS population (Primary Analysis of the 
mean post-dose response (Hour 1, 3 and 5) vs. baseline] 
















N (%) Female 11 (92%) 21 (88%) 
Mean Age in Years (SD) 37.8 (8.65) 61.1 (8.69) 
  Age Range (Years) 26-52 48-73 
Mean Weight in kg (SD) 71.5 (13.24) 69.1 (16.46) 
Mean Duration of Cough in Years 
(SD) 
N/A 14.6 (9.89) 
Duration Range (Years) N/A 3-44 




Table 2a - Mixed Model Repeated Measures Analysis for C2 and C5 Based on Natural Log-












ATP (mM)     
  Geometric Mean  18.1* 3.9 33.9** 9.2 
  Ratio (95% CI) 4.7 (2.0, 10.8)  3.7 (1.5, 9.2)  
     
Distilled Water (%)     
  Geometric Mean 83.4** 61.8 91.0** 69.1 
  Ratio (95% CI) 1.4 (1.1, 1.6)  1.3 (1.1, 1.6)  
     
Capsaicin (µM)     
  Geometric Mean 5.6 4.1 10.0 7.8 
  Ratio (95% CI) 1.4 (0.8, 2.5)  1.3 (0.7, 2.4)  
     
Citric Acid (mM)     
  Geometric Mean 58.6 46.5 114.6 86.5 
  Ratio (95% CI) 
 





Table 2b - Mixed Model Repeated Measures Analysis for C2 and C5 Based on Natural Log-













ATP (mM)     
  Geometric Mean  120.2 49.5 272.5** 113.5 
  Ratio (95% CI) 2.4 (0.8, 7.4)  2.4 (1.4, 4.0)  
     
Distilled Water (%)     
  Geometric Mean 111.9* 76.4 127.1 100.7 
  Ratio (95% CI) 1.5 (1.3, 1.7)  1.3 (0.9, 1.8)  
     
Capsaicin (µM)     
  Geometric Mean 21.1 20.8 86.8 17.7 
  Ratio (95% CI) 1.0 (0.5, 2.0)  0.8 (0.3, 1.9)  
     
Citric Acid (mM)     
  Geometric Mean 475.5 272.5 1232 914.6 
  Ratio (95% CI) 
 
1.7 (0.8, 4.0)  1.4 (0.5, 3.8)  
Treatment comparison was performed using a mixed effect repeated measures (MMRM) model. Baseline refers 
to the baseline on the log scale. Missing C2 or C5 (unable to reach) values were imputed using 1.5 x maximum 
concentration level. The geometric mean was estimated by exponentiating the LS mean (in log scale). The ratio 
of gefapixant to placebo was estimated by exponentiating the LS mean difference (in log scale). 
*P value (LS Mean Difference vs. Placebo) < 0.001; ** P value (LS Mean Difference vs. Placebo) < 0.01 
 
Table 3 – Summary of Endpoints Assessing Cough Burden in Chronic Cough Subjects upon 
Treatment with Gefapixant and Placebo 
 
 N LS Mean (95% CI) p-value 
Cough Severity  VAS    
Gefapixant 100 mg  24 -26.2 (-36.2, -16.2) -- 
Placebo 24 -8.2 (-18.7, 2.2) -- 
Gefapixant vs. Placebo -- -18.0 (-29.8, -6.2) 0.0037 
Urge-to-Cough VAS    
Gefapixant 100 mg  24 -29.8 (-38.9, -20.7)  
Placebo 24 -11.7 (-20.9, -2.6)  
Gefapixant vs. Placebo -- -18 (-29.1, -7.0) 0.0020 
HARQ Total Score    
Gefapixant 100 mg  24 -16.2 (-22.1, -10.3)  
Placebo 24 -11.0 (-17.0, -5.1)  
Gefapixant vs. Placebo -- -5.2 (-10.9, 0.6) 0.0766 
Cough Frequency over 24 
Hours (coughs/hr) 
   
Gefapixant 100 mg  24 -7.7 (-10.1, -5.3)  
Placebo 22 -4.1 (-6.5, -1.7)  
Gefapixant vs. Placebo -- -3.6 (-6.2, -1.0) 0.0075 
Mixed effect model includes fixed effects for treatment group, period, the treatment-




Table 4 – Summary of Adverse Events 
 Healthy Subjects Chronic Cough Subjects 








Any AEs 12 (100.0%) 6 (50.0%) 23 (95.8%) 8 (33.3%) 
Serious AEs or AEs leading to 
Discontinuation 
0 0 0 0 
Most Frequent AEs 
  Dysgeusia 9  (75.0%) 1  ( 8.3%) 16  (66.7%) 0 
  Ageusia 6  (50.0%) 1  ( 8.3%) 7  (29.2%) 0 
  Dry Mouth 4  (33.3%) 0 6  (25.0%) 1  ( 4.2%) 
  Hypoaesthesia (Oral) 3  (25.0%) 0 4  (16.7%) 0 
  Headache 0 3 (25.0%) 6 (25.0%) 2 (8.3%) 















Subjects were not eligible if they had a history of upper respiratory tract infection (URTI) or 
recent significant change in pulmonary status within 4 weeks of the Baseline Visit (Day 0); had acute 
worsening of asthma; did not cough during the ATP, capsaicin, or citric acid challenge at screening or 
only coughed twice at the 2 highest concentrations of the test solution; or demonstrated > 2 coughs 
to inhalation of the normal saline solution during the baseline challenge. Subjects were not eligible 
for this study if they had a history or symptoms of renal disease or renal obstructive disease. 
Angiotensin converting enzyme (ACE)-inhibitors within 4 weeks of the study or opioid use within 1 
week of the baseline visit were not permitted.  
